

Bernard H Bochner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7586132/publications.pdf>

Version: 2024-02-01

240
papers

26,499
citations

12330

69
h-index

6471

157
g-index

255
all docs

255
docs citations

255
times ranked

23264
citing authors

#	ARTICLE	IF	CITATIONS
1	Definition of a Structured Training Curriculum for Robot-assisted Radical Cystectomy with Intracorporeal Ileal Conduit in Male Patients: A Delphi Consensus Study Led by the ERUS Educational Board. <i>European Urology Focus</i> , 2022, 8, 160-164.	3.1	21
2	Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy. <i>BJU International</i> , 2022, 129, 463-469.	2.5	9
3	Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort. <i>European Urology</i> , 2022, 81, 294-304.	1.9	33
4	Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1312-1322.	1.6	42
5	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
6	Feasibility of a geriatric comanagement (GERICO) pilot program for patients 75 and older undergoing radical cystectomy. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1427-1432.	1.0	8
7	Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 431-441.	1.9	5
8	Urethral Melanoma – Clinical, Pathological and Molecular Characteristics. <i>Bladder Cancer</i> , 2022, 8, 291-301.	0.4	1
9	Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. <i>JCO Precision Oncology</i> , 2022, , .	3.0	6
10	Ureteroenteric stricture outcomes: secondary analysis of a randomised controlled trial comparing open versus robot-assisted radical cystectomy. <i>BJU International</i> , 2022, 130, 809-814.	2.5	3
11	Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.07.016 . <i>European Urology</i> , 2021, 79, e56-e57.	1.9	0
12	Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy. <i>Journal of Urology</i> , 2021, 205, 400-406.	0.4	6
13	Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4599-4609.	7.0	26
14	CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. <i>Bladder Cancer</i> , 2021, 7, 1-6.	0.4	2
15	Management of Common Complications After Radical Cystectomy, Lymph Node Dissection, and Urinary Diversion. , 2021, , 185-203.		0
16	Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 1214-1221.	6.4	14
17	Predictors of Benign Ureteroenteric Anastomotic Strictures After Radical Cystectomy and Urinary Diversion. <i>Urology</i> , 2020, 144, 225-229.	1.0	22
18	Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. <i>European Urology</i> , 2020, 77, 1-2.	1.9	3

#	ARTICLE	IF	CITATIONS
19	Lymph Node Dissection for Advanced Bladder Cancer: Is There a Role?. European Urology Focus, 2020, 6, 615-616.	3.1	2
20	A Population-based Study of Ureteroenteric Strictures After Open and Robot-assisted Radical Cystectomy. Urology, 2020, 135, 57-65.	1.0	37
21	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. Journal of Clinical Oncology, 2020, 38, 406-414.	1.6	60
22	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort. European Urology, 2020, 77, 223-250.	1.9	132
23	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. European Urology, 2020, 78, 907-915.	1.9	21
24	Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. European Urology, 2020, 77, 669-670.	1.9	30
25	Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2020, 3, 306-315.	5.4	97
26	Expeditious Radical Cystectomy in Patients with High-risk Bladder Cancer Remains an Important Part of Patient Care. European Urology Oncology, 2020, 3, 250-251.	5.4	0
27	Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience. Clinical Genitourinary Cancer, 2020, 18, 387-394.	1.9	32
28	Primary urethral cancer: treatment patterns and associated outcomes. BJU International, 2020, 126, 359-366.	2.5	7
29	Ileal conduit or orthotopic neobladder: selection and contemporary patterns of use. Current Opinion in Urology, 2020, 30, 415-420.	1.8	25
30	AUTHOR REPLY. Urology, 2020, 135, 65.	1.0	0
31	Goal-directed <i>versus</i> Standard Fluid Therapy to Decrease Ileus after Open Radical Cystectomy. Anesthesiology, 2020, 133, 293-303.	2.5	25
32	Utility of Routine Preoperative ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy. Journal of Urology, 2020, 204, 254-259.	0.4	19
33	Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations. Journal of Urology, 2020, 204, 460-465.	0.4	2
34	Trends in Management and Outcomes among Patients with Urothelial Carcinoma Undergoing Radical Cystectomy from 1995 to 2015: The Memorial Sloan Kettering Experience. Journal of Urology, 2020, 204, 677-684.	0.4	13
35	Reply by Authors. Journal of Urology, 2020, 204, 259-259.	0.4	0
36	Reply by Authors. Journal of Urology, 2020, 204, 684-684.	0.4	0

#	ARTICLE	IF	CITATIONS
37	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World Journal of Urology, 2019, 37, 51-60.	2.2	31
38	Reply to Siebren Dijkstra and Carl J. Wijkstra's Letter to the Editor re: Bernard H. Bochner, Guido Dalbagni, Karim H. Marzouk, et al. Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. Eur Urol 2018;74:465-471. Can the Pattern of Cancer Recurrence Truly be Assigned to the Surgical Modality?. European Urology, 2019, 75, e138-e139.	1.9	1
39	A Thoughtful Pause for Sparing Oophorectomy. Urology, 2019, 129, 237.	1.0	0
40	Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. Journal of Pathology, 2019, 248, 260-265.	4.5	37
41	The Outcome of Post-Chemotherapy Retroperitoneal Lymph Node Dissection in Patients with Metastatic Bladder Cancer in the Retroperitoneum. Bladder Cancer, 2019, 5, 13-19.	0.4	6
42	Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy. World Journal of Urology, 2019, 37, 2401-2407.	2.2	7
43	Leveraging Latent Dirichlet Allocation in processing free-text personal goals among patients undergoing bladder cancer surgery. Quality of Life Research, 2019, 28, 1441-1455.	3.1	34
44	Evolution in technique of robotic intracorporeal continent catheterizable pouch after cystectomy. Urology Video Journal, 2019, 4, 100020.	0.2	2
45	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology. American Journal of Surgical Pathology, 2019, 43, 920-927.	3.7	59
46	Update of the ICUD-SIU International Consultation on Bladder Cancer 2018: urinary diversion. World Journal of Urology, 2019, 37, 85-93.	2.2	21
47	Perceptions of Response Burden Associated with Completion of Patient-Reported Outcome Assessments in Oncology. Value in Health, 2019, 22, 225-230.	0.3	38
48	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
49	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clinical Cancer Research, 2019, 25, 967-976.	7.0	164
50	Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. European Urology, 2019, 75, 231-239.	1.9	104
51	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. European Urology Focus, 2019, 5, 201-204.	3.1	30
52	The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy. European Urology Focus, 2019, 5, 104-108.	3.1	58
53	Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens. European Urology Focus, 2019, 5, 365-368.	3.1	20
54	Development and validation of surgical training tool: cystectomy assessment and surgical evaluation (CASE) for robot-assisted radical cystectomy for men. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 4458-4464.	2.4	12

#	ARTICLE	IF	CITATIONS
55	Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis. Cancer, 2018, 124, 2507-2514.	4.1	13
56	Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy. BJU International, 2018, 122, 627-632.	2.5	24
57	Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. World Journal of Urology, 2018, 36, 645-653.	2.2	2
58	Postchemotherapy Surgery for Advanced Urothelial Cancer: Another Tool To Improve Outcome. European Urology, 2018, 73, 558-559.	1.9	1
59	Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 213-218.	1.9	13
60	Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Human Pathology, 2018, 77, 63-69.	2.0	27
61	Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e113-e120.	1.9	7
62	Male Neobladder. Urologic Clinics of North America, 2018, 45, 37-48.	1.8	4
63	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clinical Cancer Research, 2018, 24, 1965-1973.	7.0	85
64	Clinical Outcomes of Patients With T1 Nested Variant of Urothelial Carcinoma Compared to Pure Urothelial Carcinoma of the Bladder. Clinical Genitourinary Cancer, 2018, 16, e23-e27.	1.9	19
65	Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. JCO Precision Oncology, 2018, 2018, 1-13.	3.0	29
66	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 2018, 36, 1949-1956.	1.6	110
67	Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device. Urology, 2018, 122, 121-126.	1.0	5
68	Randomized Trial Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: Oncologic Outcomes. European Urology, 2018, 74, 465-471.	1.9	189
69	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical) Tj ETQq1 1 0.784314 rgBT /Over	1.9	372
70	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World Journal of Urology, 2017, 35, 327-335.	2.2	26
71	Idiographic quality of life assessment before radical cystectomy. Psycho-Oncology, 2017, 26, 206-213.	2.3	8
72	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research, 2017, 23, 3610-3618.	7.0	225

#	ARTICLE	IF	CITATIONS
73	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473
74	Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. <i>Journal of Urology</i> , 2017, 198, 552-559.	0.4	632
75	Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin. <i>Cancer Cytopathology</i> , 2017, 125, 416-426.	2.4	26
76	Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 603.e1-603.e5.	1.6	15
77	Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma who have Progressed Following Treatment with Platinum-based Chemotherapy: A Single-arm, Multicenter, Phase 2 Trial. <i>European Urology</i> , 2017, 71, 299-300.	1.9	2
78	Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy. <i>European Urology</i> , 2017, 71, 545-557.	1.9	72
79	A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. <i>Urology</i> , 2017, 102, 164-172.	1.0	52
80	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. <i>European Urology</i> , 2017, 72, 952-959.	1.9	263
81	Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guérin (NCT01259063). <i>Bladder Cancer</i> , 2017, 3, 113-119.	0.4	13
82	Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 621-625.	2.5	40
83	Title is missing!. , 2017, , .		9
84	Complications of Ileal Conduit Diversion. , 2017, , 63-79.		2
85	Parastomal hernias after radical cystectomy and ileal conduit diversion. <i>Investigative and Clinical Urology</i> , 2016, 57, 240.	2.0	33
86	A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor. <i>Journal of Urology</i> , 2016, 196, 1014-1020.	0.4	41
87	Genomic characterization of response to chemoradiation in urothelial bladder cancer. <i>Cancer</i> , 2016, 122, 3715-3723.	4.1	50
88	Accuracy of Self-reported Smoking Exposure Among Bladder Cancer Patients Undergoing Surveillance at a Tertiary Referral Center. <i>European Urology Focus</i> , 2016, 2, 441-444.	3.1	8
89	Rationale and Early Experience with Prophylactic Placement of Mesh to Prevent Parastomal Hernia Formation after Ileal Conduit Urinary Diversion and Cystectomy for Bladder Cancer. <i>Current Urology Reports</i> , 2016, 17, 9.	2.2	28
90	Enhanced Recovery after Urological Surgery: A Contemporary Systematic Review of Outcomes, Key Elements, and Research Needs. <i>European Urology</i> , 2016, 70, 176-187.	1.9	230

#	ARTICLE	IF	CITATIONS
91	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. <i>Nature Genetics</i> , 2016, 48, 356-358.	21.4	143
92	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2016, 195, 1684-1689.	0.4	36
93	Comparison of Perioperative Outcomes for Epidural Versus Intravenous Patient-Controlled Analgesia After Radical Cystectomy. <i>Regional Anesthesia and Pain Medicine</i> , 2015, 40, 239-244.	2.3	25
94	Id Proteins Contribute to Tumor Development and Metastatic Colonization in A Model of Bladder Carcinogenesis. <i>Bladder Cancer</i> , 2015, 1, 159-170.	0.4	2
95	Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. <i>European Urology</i> , 2015, 67, 1042-1050.	1.9	453
96	Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2015, 67, 198-201.	1.9	122
97	Re: Whole-genome and Whole-exome Sequencing of Bladder Cancer Identifies Frequent Alterations in Genes Involved in Sister Chromatid Cohesion and Segregation. <i>European Urology</i> , 2015, 67, 350-351.	1.9	3
98	Best Practices in Robot-assisted Radical Cystectomy and Urinary Reconstruction: Recommendations of the Pasadena Consensus Panel. <i>European Urology</i> , 2015, 67, 363-375.	1.9	158
99	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. <i>European Urology</i> , 2015, 68, 238-253.	1.9	211
100	Quality of life and symptom assessment in randomized clinical trials of bladder cancer: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 331.e17-331.e23.	1.6	11
101	Radical Transurethral Resection Alone, Robotic or Partial Cystectomy, or Extended Lymphadenectomy. <i>Urologic Clinics of North America</i> , 2015, 42, 189-199.	1.8	7
102	Cost Comparison of Open and Robotic Partial Nephrectomy Using a Short Postoperative Pathway. <i>Urology</i> , 2015, 85, 596-604.	1.0	30
103	Genomic Characterization of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2015, 68, 970-977.	1.9	202
104	Intradiverticular bladder cancer: CT imaging features and their association with clinical outcomes. <i>Clinical Imaging</i> , 2015, 39, 94-98.	1.5	17
105	The Role of Lymphadenectomy in the Management of Urothelial Carcinoma of the Upper Urinary Tract. , 2015, , 153-178.		0
106	Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. <i>Cancer Discovery</i> , 2014, 4, 1140-1153.	9.4	506
107	Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 1873-1883.	7.0	63
108	A Randomized Trial of Robot-Assisted Laparoscopic Radical Cystectomy. <i>New England Journal of Medicine</i> , 2014, 371, 389-390.	27.0	114

#	ARTICLE	IF	CITATIONS
109	Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience. International Scholarly Research Notices, 2014, 2014, 1-6.	0.9	12
110	Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nature Reviews Urology, 2014, 11, 589-596.	3.8	69
111	Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU International, 2014, 113, 11-23.	2.5	274
112	Synthetic Lethality in ATM-Deficient <i>RAD50</i> -Mutant Tumors Underlies Outlier Response to Cancer Therapy. Cancer Discovery, 2014, 4, 1014-1021.	9.4	114
113	Risk Factors for the Development of Parastomal Hernia after Radical Cystectomy. Journal of Urology, 2014, 191, 1708-1713.	0.4	76
114	The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. World Journal of Urology, 2014, 32, 453-459.	2.2	24
115	The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nature Reviews Urology, 2014, 11, 153-162.	3.8	535
116	More on Robot-Assisted Laparoscopic Radical Cystectomy. New England Journal of Medicine, 2014, 371, 1654-1655.	27.0	4
117	Aminopeptidase activities as prospective urinary biomarkers for bladder cancer. Proteomics - Clinical Applications, 2014, 8, 317-326.	1.6	14
118	Adherence to surveillance guidelines after radical cystectomy: A population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 779-784.	1.6	12
119	Risk of Fracture After Radical Cystectomy and Urinary Diversion for Bladder Cancer. Journal of Clinical Oncology, 2014, 32, 3291-3298.	1.6	37
120	Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings. International Urology and Nephrology, 2014, 46, 1699-1705.	1.4	31
121	Editorial Comment. Urology, 2014, 83, 861-862.	1.0	0
122	Clinical Outcome of Patients with T1 Micropapillary Urothelial Carcinoma of the Bladder. Journal of Urology, 2014, 192, 702-707.	0.4	61
123	The role of PTEN tumor suppressor pathway staining in carcinoma in situ of the bladder11Funding: Supported by the Sidney Kimmel Center for Prostate and Urologic Cancer and the Michael and Zea Wiener Foundation. Dr Sfakianos is a research fellow in urologic oncology supported by NIH T32-CA82088.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 657-662.	1.6	15
124	Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046).. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 637-644.	1.6	46
125	Who should be included in a clinical trial of screening for bladder cancer?. Cancer, 2013, 119, 143-149.	4.1	35
126	Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma. BJU International, 2013, 111, 589-595.	2.5	24

#	ARTICLE	IF	CITATIONS
127	Oncologic Outcomes Achieved by Radical Cystectomy. <i>European Urology</i> , 2013, 64, 225-226.	1.9	2
128	Urinary Diversion Practice Patterns Among Certifying American Urologists. <i>Journal of Urology</i> , 2013, 189, 1042-1047.	0.4	14
129	Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3133-3140.	1.6	282
130	Upper Tract Imaging Surveillance is not Effective in Diagnosing Upper Tract Recurrence in Patients Followed for Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2013, 190, 1187-1191.	0.4	38
131	ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial Carcinoma of the Prostate. <i>European Urology</i> , 2013, 63, 81-87.	1.9	24
132	A prospective study of quality of life in patients undergoing pelvic exenteration: Interim results. <i>Gynecologic Oncology</i> , 2013, 128, 191-197.	1.4	44
133	Summary of the 6th annual bladder cancer think tank: New directions in urologic research. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 968-973.	1.6	6
134	Lymphadenectomy for Bladder Cancer at the Time of Radical Cystectomy. <i>European Urology</i> , 2013, 64, 266-276.	1.9	62
135	Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. <i>BJU International</i> , 2013, 111, E325-30.	2.5	78
136	Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guérin Treatment Failure. <i>Journal of Urology</i> , 2013, 190, 1686-1691.	0.4	40
137	Towards risk stratification in bladder cancer. <i>Nature Reviews Urology</i> , 2013, 10, 374-375.	3.8	0
138	Does minimally invasive surgery for radical cystectomy provide similar long-term cancer control as open radical surgery?. <i>Current Opinion in Urology</i> , 2013, 23, 449-455.	1.8	6
139	A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2012, 62, 523-533.	1.9	214
140	Technical Advances in Bladder Cancer Patient Care: Progress or Promise?. <i>European Urology</i> , 2012, 62, 814-815.	1.9	3
141	Genome Sequencing Identifies a Basis for Everolimus Sensitivity. <i>Science</i> , 2012, 338, 221-221.	12.6	681
142	Pubovesical Fistula: A Rare Complication After Treatment of Prostate Cancer. <i>Urology</i> , 2012, 80, 446-451.	1.0	53
143	Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1323-1333.	7.0	177
144	Initial Results with 11C-Acetate Positron Emission Tomography/Computed Tomography (PET/CT) in the Staging of Urinary Bladder Cancer. <i>Molecular Imaging and Biology</i> , 2012, 14, 245-251.	2.6	51

#	ARTICLE	IF	CITATIONS
145	Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU International, 2012, 109, 77-82.	2.5	164
146	Lymph Node-Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity. European Urology, 2012, 61, 1025-1030.	1.9	98
147	Pelvic exenteration with curative intent for recurrent uterine malignancies. Gynecologic Oncology, 2012, 124, 42-47.	1.4	63
148	Re: "Pelvic exenteration with curative intent for recurrent uterine malignancies". Gynecologic Oncology, 2012, 126, 312-313.	1.4	0
149	Muscle-Invasive Urothelial Carcinoma: Conventional and Variant Subtypes. , 2012, , 143-163.		0
150	A Plea for a Uniform Surveillance Schedule After Radical Cystectomy. Journal of Urology, 2011, 185, 2091-2096.	0.4	17
151	Bladder cancer imaging. Current Opinion in Urology, 2011, 21, 393-397.	1.8	10
152	Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical cystectomy following systemic chemotherapy. BJU International, 2011, 108, E272-E277.	2.5	14
153	The Role of Laparoscopic and Robotic Cystectomy in the Management of Muscle-Invasive Bladder Cancer With Special Emphasis on Cancer Control and Complications. European Urology, 2011, 60, 767-775.	1.9	145
154	The psychological context of quality of life: a psychometric analysis of a novel idiographic measure of bladder cancer patients' personal goals and concerns prior to surgery. Health and Quality of Life Outcomes, 2011, 9, 10.	2.4	27
155	Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. Journal of Pathology, 2011, 224, 270-279.	4.5	73
156	Standardizing the care of invasive bladder cancer. Nature Reviews Clinical Oncology, 2011, 8, 454-455.	27.6	3
157	Intravesical Fiducial Marker Placement to Facilitate Image-Guided Radiation Therapy for Patients With Muscle-Invasive Bladder Cancer. UroToday International Journal, 2011, 04, .	0.1	0
158	The effect of age on bladder cancer incidence, prognosis and therapy. Aging Health, 2010, 6, 649-659.	0.3	7
159	Re: Outcome After Radical Cystectomy with Limited or Extended Pelvic Lymph Node Dissection. European Urology, 2010, 57, 175.	1.9	2
160	A Critical Analysis of Orthotopic Bladder Substitutes in Adult Patients with Bladder Cancer: Is There a Perfect Solution?. European Urology, 2010, 58, 374-383.	1.9	52
161	Changes in Renal Function Following Nephroureterectomy May Affect the Use of Perioperative Chemotherapy. European Urology, 2010, 58, 581-587.	1.9	227
162	The Effect of Tumor Location on Prognosis in Patients Treated with Radical Nephroureterectomy at Memorial Sloan-Kettering Cancer Center. European Urology, 2010, 58, 574-580.	1.9	159

#	ARTICLE	IF	CITATIONS
163	Comparison Between Laparoscopic and Open Radical Nephroureterectomy in a Contemporary Group of Patients: Are Recurrence and Disease-Specific Survival Associated with Surgical Technique?. European Urology, 2010, 58, 645-651.	1.9	98
164	The effect of age and gender on bladder cancer: a critical review of the literature. BJU International, 2010, 105, 300-308.	2.5	281
165	Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma. BJU International, 2010, 106, 1502-1507.	2.5	11
166	Clinical Outcome of Primary Versus Secondary Bladder Carcinoma In Situ. Journal of Urology, 2010, 184, 464-469.	0.4	35
167	Clinical Outcomes of Primary Bladder Carcinoma In Situ in a Contemporary Series. Journal of Urology, 2010, 184, 74-80.	0.4	48
168	Oncological Outcomes After Radical Cystectomy for Bladder Cancer: Open Versus Minimally Invasive Approaches. Journal of Urology, 2010, 183, 862-870.	0.4	74
169	Overview of SUO Winter 2008 proceedings. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 67-68.	1.6	0
170	Impact of Previous Radiotherapy for Prostate Cancer on Clinical Outcomes of Patients With Bladder Cancer. Journal of Urology, 2010, 183, 1751-1756.	0.4	26
171	Does DW-MRI have a role in the evaluation of hematuria?. Nature Reviews Urology, 2009, 6, 469-470.	3.8	2
172	Bladder Cancer: Narrowing the Gap Between Evidence and Practice. Journal of Clinical Oncology, 2009, 27, 5680-5684.	1.6	56
173	Potential Impact of Postoperative Early Complications on the Timing of Adjuvant Chemotherapy in Patients Undergoing Radical Cystectomy: A High-Volume Tertiary Cancer Center Experience. European Urology, 2009, 55, 177-186.	1.9	227
174	Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting Methodology. European Urology, 2009, 55, 164-176.	1.9	1,145
175	Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1 Bladder Cancer. European Urology, 2009, 56, 903-910.	1.9	111
176	Clinical benefits of a multivariate prediction model for bladder cancer. Cancer, 2009, 115, 5460-5469.	4.1	32
177	Optimal timing of radical cystectomy for patients with T1 bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 329-331.	1.6	16
178	Ureteroileocecal Appendicostomy Based Urinary Reservoir in Irradiated and Nonirradiated Patients. Journal of Urology, 2009, 182, 2376-2381.	0.4	11
179	Identification of Nodal Metastases: The role of Iron Oxide Enhanced MRI. , 2009, , 67-77.		0
180	Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer, 2008, 112, 2384-2392.	4.1	281

#	ARTICLE	IF	CITATIONS
181	A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder. <i>Cancer</i> , 2008, 113, 2471-2477.	4.1	239
182	Risk Assessment of Prostatic Pathology in Patients Undergoing Radical Cystoprostatectomy. <i>European Urology</i> , 2008, 53, 370-375.	1.9	90
183	Longitudinal Risk of Upper Tract Recurrence Following Radical Cystectomy for Urothelial Cancer and the Potential Implications for Long-Term Surveillance. <i>Journal of Urology</i> , 2008, 179, 96-100.	0.4	73
184	Gene therapy in bladder cancer. <i>Current Opinion in Urology</i> , 2008, 18, 519-523.	1.8	15
185	Bladder cancer: can imaging change patient management?. <i>Current Opinion in Urology</i> , 2008, 18, 98-104.	1.8	36
186	How prevalent is neobladder emptying failure, and how can it be treated?. <i>Nature Reviews Urology</i> , 2007, 4, 364-365.	1.4	0
187	Highly Efficient Gene Delivery for Bladder Cancers by Intravesically Administered Replication-Competent Retroviral Vectors. <i>Clinical Cancer Research</i> , 2007, 13, 4511-4518.	7.0	29
188	Adenoviral Receptor Expression of Normal Bladder and Transitional Cell Carcinoma of the Bladder. <i>Urologia Internationalis</i> , 2007, 78, 160-166.	1.3	24
189	Prospective Trial of Ifosfamide, Paclitaxel, and Cisplatin in Patients with Advanced Non-transitional Cell Carcinoma of the Urothelial Tract. <i>Urology</i> , 2007, 69, 255-259.	1.0	79
190	The use and abuse of data: Nomograms and talking to patients about clinical medicine. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 333-337.	1.6	9
191	Genomic and Proteomic Profiles Reveal the Association of Gelsolin to TP53 Status and Bladder Cancer Progression. <i>American Journal of Pathology</i> , 2007, 171, 1650-1658.	3.8	30
192	Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer. <i>Journal of Urology</i> , 2007, 177, 1283-1286.	0.4	146
193	Urachal Carcinoma: Contemporary Surgical Outcomes. <i>Journal of Urology</i> , 2007, 178, 74-78.	0.4	137
194	Prognostic significance of p27Kip1 expression in bladder cancer. <i>BJU International</i> , 2007, 100, 259-263.	2.5	33
195	Evaluation of regional lymph node dissection in patients with upper urinary tract urothelial cancer. <i>International Journal of Urology</i> , 2007, 14, 26-32.	1.0	57
196	Detection and Management of Isolated Lymph Node Recurrence in Patients with PSA Relapse. <i>European Urology</i> , 2007, 52, 310-312.	1.9	2
197	Radical Cystectomy and Lymphadenectomy for Invasive Bladder Cancer: Towards the Evolution of an Optimal Surgical Standard. <i>Seminars in Oncology</i> , 2007, 34, 110-121.	2.2	19
198	Association Between Urinary Cytology and Pathology for Nontransitional Cell Malignancies of the Urinary Tract. <i>Journal of Urology</i> , 2006, 175, 2038-2041.	0.4	10

#	ARTICLE	IF	CITATIONS
199	Safety and Efficacy of Intravesical Bacillus Calmette-Guerin Instillations in Steroid Treated and Immunocompromised Patients. Journal of Urology, 2006, 176, 482-485.	0.4	52
200	Natural History of Positive Urinary Cytology After Radical Cystectomy. Journal of Urology, 2006, 176, 2000-2005.	0.4	25
201	Superficial and Muscle-Invasive Bladder Cancer: Principles of Management for Outcomes Assessments. Journal of Clinical Oncology, 2006, 24, 5519-5527.	1.6	88
202	Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer. Nature Clinical Practice Oncology, 2006, 3, 474-475.	4.3	4
203	Importance of Node Dissection in Relation to Neoadjuvant and Adjuvant Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 1019-1026.	4.9	1
204	Is lymphovascular invasion an important prognostic factor in patients with bladder cancer?. Nature Reviews Urology, 2006, 3, 188-189.	1.4	0
205	Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. BJU International, 2006, 98, 59-62.	2.5	47
206	Use of nomograms as predictive tools in bladder cancer. World Journal of Urology, 2006, 24, 489-498.	2.2	13
207	Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer, 2006, 107, 506-513.	4.1	360
208	Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer. Cancer, 2006, 107, 2167-2172.	4.1	69
209	Standardization of pelvic lymphadenectomy performed at radical cystectomy. Cancer, 2006, 107, 2368-2374.	4.1	215
210	Multimodal therapy for urologic cancers. Nature Reviews Urology, 2006, 3, 453-453.	1.4	1
211	Postoperative Nomogram Predicting Risk of Recurrence After Radical Cystectomy for Bladder Cancer. Journal of Clinical Oncology, 2006, 24, 3967-3972.	1.6	419
212	Phase II Trial of Intravesical Gemcitabine in Bacille Calmette-Guérin-Refractory Transitional Cell Carcinoma of the Bladder. Journal of Clinical Oncology, 2006, 24, 2729-2734.	1.6	160
213	Current status of establishing standards for lymphadenectomy in the treatment of bladder cancer. Current Opinion in Urology, 2005, 15, 315-319.	1.8	11
214	Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecologic Oncology, 2005, 99, 608-614.	1.4	148
215	DOES BODY MASS INDEX AFFECT SURVIVAL OF PATIENTS UNDERGOING RADICAL OR PARTIAL CYSTECTOMY FOR BLADDER CANCER?. Journal of Urology, 2005, 173, 1513-1517.	0.4	62
216	HERPES SIMPLEX VIRUS BASED GENE THERAPY ENHANCES THE EFFICACY OF MITOMYCIN C FOR THE TREATMENT OF HUMAN BLADDER TRANSITIONAL CELL CARCINOMA. Journal of Urology, 2005, 174, 741-746.	0.4	30

#	ARTICLE	IF	CITATIONS
217	Inhibition of Orthotopic Human Bladder Tumor Growth by Lentiviral Gene Transfer of Endostatin. <i>Clinical Cancer Research</i> , 2004, 10, 1835-1842.	7.0	32
218	Detection of Methylated Apoptosis-Associated Genes in Urine Sediments of Bladder Cancer Patients. <i>Clinical Cancer Research</i> , 2004, 10, 7457-7465.	7.0	202
219	Use of an ureteroileocecal appendicostomy urinary reservoir in patients with recurrent pelvic malignancies treated with radiation. <i>Gynecologic Oncology</i> , 2004, 94, 140-146.	1.4	12
220	PARTIAL CYSTECTOMY: A CONTEMPORARY REVIEW OF THE MEMORIAL SLOAN-KETTERING CANCER CENTER EXPERIENCE AND RECOMMENDATIONS FOR PATIENT SELECTION. <i>Journal of Urology</i> , 2004, 172, 878-881.	0.4	151
221	PROSPECTIVELY PACKAGED LYMPH NODE DISSECTIONS WITH RADICAL CYSTECTOMY: EVALUATION OF NODE COUNT VARIABILITY AND NODE MAPPING. <i>Journal of Urology</i> , 2004, 172, 1286-1290.	0.4	193
222	BLADDER CANCER AS A PROGNOSTIC FACTOR FOR UPPER TRACT TRANSITIONAL CELL CARCINOMA. <i>Journal of Urology</i> , 2004, 172, 2177-2181.	0.4	89
223	Importance of lymph node dissection in urologic cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004, 22, 197.	1.6	0
224	274: Phase II Trial of Intra Vesical Gemcitabine in BCG-Refractory Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2004, 171, 72-72.	0.4	9
225	Follow-up strategies and management of recurrence in urologic oncology bladder cancer:. <i>Urologic Clinics of North America</i> , 2003, 30, 777-789.	1.8	61
226	Detection and Quantitative Analysis of Early Stage Orthotopic Murine Bladder Tumor Using In Vivo Magnetic Resonance Imaging. <i>Journal of Urology</i> , 2003, 170, 1375-1378.	0.4	32
227	Orthotopic Urinary Diversion After Cystectomy For Bladder Cancer: Implications For Cancer Control And Patterns Of Disease Recurrence. <i>Journal of Urology</i> , 2003, 169, 177-181.	0.4	97
228	Umbilical Endometriosis. <i>Journal of Urology</i> , 2003, 170, 2388-2389.	0.4	12
229	Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. <i>Journal of Urology</i> , 2003, 169, 177-81.	0.4	28
230	International Validation of a Preoperative Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2002, 20, 3206-3212.	1.6	203
231	Tissue-Specific Transcriptional Targeting of a Replication-Competent Retroviral Vector. <i>Journal of Virology</i> , 2002, 76, 12783-12791.	3.4	51
232	IMPACT OF THE NUMBER OF LYMPH NODES RETRIEVED ON OUTCOME IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2002, 167, 1295-1298.	0.4	544
233	Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. <i>Journal of Urology</i> , 2002, 167, 1295-8.	0.4	133
234	IMPACT OF SEPARATE VERSUS EN BLOC PELVIC LYMPH NODE DISSECTION ON THE NUMBER OF LYMPH NODES RETRIEVED IN CYSTECTOMY SPECIMENS. <i>Journal of Urology</i> , 2001, 166, 2295-2296.	0.4	232

#	ARTICLE	IF	CITATIONS
235	NOREPINEPHRINE PRODUCING RENAL CELL CARCINOMA. Journal of Urology, 2001, 166, 603-603.	0.4	0
236	Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients. Journal of Clinical Oncology, 2001, 19, 666-675.	1.6	3,157
237	Development of lentiviral vectors for antiangiogenic gene delivery. Cancer Gene Therapy, 2001, 8, 879-889.	4.6	58
238	AN ALTERNATIVE URETEROILEAL REIMPLANTATION USED IN AUGMENTATION CYSTOPLASTY FOR NEUROGENIC BLADDER WITH BILATERAL VESICoureTERAL REFLUX. Journal of Urology, 1998, 160, 1416-1417.	0.4	2
239	SALVAGE RADICAL CYSTOPROSTATECTOMY AND ORTHOTOPIC URINARY DIVERSION FOLLOWING RADIATION FAILURE. Journal of Urology, 1998, 160, 29-33.	0.4	88
240	THE T POUCH: AN ORTHOTOPIC ILEAL NEOBLADDER INCORPORATING A SEROSAL LINED ILEAL ANTIREFLUX TECHNIQUE. Journal of Urology, 1998, 159, 1836-1842.	0.4	133